MTOX1018
BSEP Knockout HepaRG™ Cells
1 vial
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
NACRES:
NA.81
UNSPSC Code:
12352207
biological source
human female liver (Source Disease: Hepatocarcinoma and Hepatitis C)
form
liquid
storage temp.
−196°C
Gene Information
human ... ABCB11(1351619)
General description
HepaRG is a human hepatoma cell line. The cells possess a pseudodiploid karyotype and have been characterized as an oval ductular bipotent hepatic cell line as they have the ability to differentiate into both biliary and hepatocyte lineages in the presence of DMSO. HepaRG BSEP knockout cells express the major xenobiotic sensors (PXR, CAR and AhR), drug transporters, phase I and II drug metabolizing enzymes as well as key hepatic transcription factors involved in stress response pathways.
Application
See technical bulletin for detailed protocols
Features and Benefits
HepaRG cells are the most metabolically active human hepatocyte cell line developed to date. These the cells are suitable for a wide variety of studies for drug metabolism, CYP induction, metabolism-mediated toxicity, transporter, cholestasis, and hepatotoxicity.
- Sigma′s HepaRG BSEP Knockout (KO) allows investigations of drug-transporter interactions and bile acid biosynthesis, accumulation (Cholestasis), and transport involving BSEP in the liver.
Zinc finger nucleases (ZFN) mediated Knock-out of ABCB11 (BSEP) gene.
- The frame-shift mutation of ABCB11 gene was confirmed by fragment length analysis and DNA sequencing.
- Loss of functionality was confirmed by loss of transport of selective substrates in sandwich culture assay.
Analysis Note
Tested for Mycoplasma, sterility, post-freeze viability, short terminal repeat (STR) analysis for cell line identification, cytochrome oxidase I (COI) analysis for cell line species confirmation
Legal Information
These products are covered by the License Agreement as described in Exhibit 1 and 2, in the technical bulletin.
HepaRG is a trademark of BioPredic International company
Storage Class
12 - Non Combustible Liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tristan M Sissung et al.
Molecular pharmacology, 96(2), 158-167 (2019-06-09)
Mithramycin demonstrates preclinical anticancer activity, but its therapeutic dose is limited by the development of hepatotoxicity that remains poorly characterized. A pharmacogenomics characterization of mithramycin-induced transaminitis revealed that hepatotoxicity is associated with germline variants in genes involved in bile disposition:
Xi Qiu et al.
Molecular pharmaceutics, 13(4), 1206-1216 (2016-02-26)
In the present study, we characterized in vitro biosynthesis and disposition of bile acids (BAs) as well as hepatic transporter expression followed by ABCB11 (BSEP) gene knockout in HepaRG cells (HepaRG-KO cells). BSEP KO in HepaRG cells led to time-dependent
Tristan M Sissung et al.
Molecular pharmacology, 96(2), 158-167 (2019-06-09)
Mithramycin demonstrates preclinical anticancer activity, but its therapeutic dose is limited by the development of hepatotoxicity that remains poorly characterized. A pharmacogenomics characterization of mithramycin-induced transaminitis revealed that hepatotoxicity is associated with germline variants in genes involved in bile disposition:
Articles
Oral drug delivery involves dissolution in the small intestine and absorption across the enterocyte barrier into the portal vein followed by subsequent delivery through the liver into the systemic circulation.
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service